Recombinant Cynomolgus PD-L1/B7-H1/CD274

英文名 ：Recombinant Cynomolgus PD-L1/B7-H1/CD274

规格 ：10ug/50ug/500ug/1mg

Recombinant Cynomolgus PD-L1/B7-H1/CD274 (CC29)

产品说明(Description)

Recombinant Cynomolgus Putative uncharacterized protein is produced by our Mammalian expression systemand the target gene encoding Phe19-Thr239 is expressed with a 6His tag at the C-terminus.

Accession #: G7PSE7

Known as: B7-H; B7H1; B7-H1; PDCD1L1; CD274 molecule; CD274; PDCD1L1; PDCD1LG1; PDL1; PD-L1; PD-L1B7 homolog 1; PDL1PDCD1 ligand 1; programmed cell death 1 ligand 1; Programmed death ligand 1

 

制剂(Formulation)

Lyophilized from a 0.2 μm filtered solution of PBS, pH7.4.

 

质量控制(Quality Control)

Purity:        Greater than 90% as determined by reducing SDS-PAGE.    

Endotoxin: Less than 0.1 ng/μg (1 EU/μg).

Bioactivity-BLI:

 

Loaded Cynomolgus PD-L1-His(Cat#CC29) on HIS1K Biosensor, can bind Anti-Human PDL1 mAb-Fc(Cat#NC014) with an affinity constant of <10-3 nM as determined in BLI assay.

 

复溶(Reconstitution) 

 

Always centrifuge tubes before opening. Do not mix by vortex or pipetting.
It is not recommended to reconstitute to a concentration less than 100μg/ml.
Dissolve the lyophilized protein in distilled water.
Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

 

 

保存(Storage)

Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks.
Reconstituted protein solution can be stored at 4-7°C for 2-7 days.
Aliquots of reconstituted samples are stable at < -20°C for 3 months.     

 

背景(Background)

 

 

CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.

 

电泳(SDS-PAGE)

 

FOR RESEARCH USE ONLY